As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" ...

Novartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction (HFpEF) and isn’t letting a missed endpoint scupper the programme.

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

A new analysis presented at the ACC 2025 meeting also finds that the new prices for heart failure drugs negotiated through Medicare will reduce hospitalizations. More Medicare Part D patients will ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent ...

sent a federal judge competing letters clashing over whether the district court must wait for MSN’s push to get a key patent for Novartis’ Entresto delisted from the FDA’s approved-drugs ... MSN from ...

Two new studies add to mounting evidence that people who use cannabis are more likely to suffer a heart attack than people who do not use the ... Mar. 18, 2025 — Lifestyle and health factors ...

MSN Laboratories Pvt. Ltd. asked a New Jersey federal judge to pause a court order blocking its “Novadoz”-branded copy of Novartis AG’s Entresto while it appeals the preliminary injunction Novartis ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental Despite medical advances, heart disease has remained the leading cause of death in the U.S. for more than a century, ...